2024-02-20 09:32:32 ET
DENVER, Colo., Feb 20, 2024 (www.247marketnews.com)- Clearmind Medicine Inc. (NASDAQ: CMND ) jointly announced, this morning, with SciSparc Ltd. (NASDAQ: SPRC ), that Clearmind filed three patent applications, under the international Patent Cooperation Treaty, which were previously filed by Clearmind as provisional patent applications with the United States Patent and Trademark Office.
“Clearmind continues to be at the forefront of the psychedelic market with one of the largest IP portfolios in the industry. The PCT makes it possible for us to seek patent protection for our proprietary compounds in a large number of countries simultaneously which strengthens our IP portfolio. To date, our ongoing collaboration with SciSparc has led to the submission of 11 different patent applications, allowing us to continue to be at the forefront of research in the psychedelic industry while working on more effective and safer treatments,” said Clearmind’s Chief Executive Officer, Dr. Adi Zuloff-Shani.
These applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA), the active ingredient of SciSparc’s proprietary CannAmide.
“We are pleased to continue our ongoing collaboration with Clearmind by expanding the intellectual property portfolio, which is an important asset,” said SciSparc’s Chief Executive Officer, Oz Adler. “We believe in the added value that CannAmide™ can offer when combined with various psychedelic compounds that are known for their therapeutics advantages.”
Clearmind Medicine is trading at $1.64, up $0.33 (+25.19%), on 8.53M premarket shares.
Its 52-week range is $0.9205 to $151.254. It hit its 52-week low last month and its premarket high is $2.65, so watch to see if this fade continues or if it can strengthen going in this morning’s regular trading session.
The post Clearmind Strengthens International Patent Portfolio first appeared on 24/7 MarketNews .
For further details see:
Clearmind Strengthens International Patent Portfolio